Full Press Release Details
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit.
SGMT
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
Key Takeaway: Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
Price reaction · baseline $3.76 (2024-09-11 close) · hit after-hours · clean, no other SGMT news in the window
day 0 close
-9.6%
day 1
-1.1%
day 3 · peak
-10.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+110%
120-day peak, hindsight
Typical move
5.7%
average across 12 past catalysts
Cash runway
~69 mo
Minimal dilution risk
Lead asset
TVB-2640
Phase 2 · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease